Development of an in-vitro patient-specific diagnostic simulator for vascular diseases and their interventions

预计到2030年，心血管疾病仍将是全球死亡的主要原因。在加拿大，每四例死亡中就有一例是心血管疾病造成的，心血管疾病每年给加拿大经济造成的损失超过220亿加元。由于心血管疾病的患病率随着年龄的增长而增加，随着加拿大人口的老龄化，心血管疾病对加拿大经济的负面影响将日益增长。诊断是心血管疾病成本的重要和重复贡献者。在这个项目中，开发了一种低成本的心血管疾病快速诊断计算工具，这个项目确实挽救了加拿大人的生命，创造了就业机会，并为加拿大带来了经济增长。该项目能够开发：（1）用于低成本心血管疾病诊断的快速计算工具;（2）用于规划对患者无风险的临床干预的预测工具。该工具将在对身体进行不可逆手术之前预测干预方案对每位患者心血管系统功能的影响。这种预测工具在全球范围内需求很高，以指导个性化干预;（3）监管医疗器械测试机。这台机器可以通过在体外执行许多重要的体内评估程序来满足医疗器械公司的测试需求，并将显着减少对动物研究和人体试验的需求，因此它可以显着加快器械批准过程，并减少新医疗器械的上市时间和上市成本。因此，这台机器将增加加拿大在医疗设备市场的份额，因为这些设备的制造商需要进行监管设计和耐久性测试，以便在将其医疗设备推向市场之前获得批准。

Cardiovascular disease is expected to remain the leading cause of death by 2030 globally. In Canada, one in every four deaths is a result of cardiovascular disease and cardiovascular disease costs the Canadian economy more than $22 billion annually. Because the prevalence of cardiovascular disease increases with age, with the Canadian aging population, the negative impact of cardiovascular disease on the Canadian economy will increasingly grow. Diagnosis is a significant and repeated contributor to cardiovascular disease costs. In this project, a rapid computational tool for low-cost cardiovascular disease diagnosis is developed.This project indeed saves Canadian lives, creates jobs, and brings economic growth to Canada. This project enables the development of: (1) a rapid computational tool for low-cost cardiovascular disease diagnosis; (2) a predictive tool for planning clinical interventions at no risk to the patients. The tool will predict the effects of intervention scenarios on the cardiovascular system's function of each patient before performing an irreversible procedure on the body. Such a predictive tool is in high demand worldwide to guide personalized interventions; (3) a regulatory medical-device testing machine. This machine can serve the testing needs of medical-device companies by making it possible to perform many important in vivo evaluation routines in vitro and will significantly reduce the need for animal studies and human trials so it can significantly speed up the device approval process and reduce the time-to-market and cost-to-market for new medical devices. This machine, therefore, will increase Canada's share in the medical devices market as the manufacturers of these devices need to perform regulatory design and durability tests to receive approvals before releasing their medical devices to the market.